CYTR Share Price

Open 0.56 Change Price %
High 0.57 1 Day 0.00 0.00
Low 0.54 1 Week -0.07 -10.94
Close 0.57 1 Month -0.03 -5.00
Volume 4451925 1 Year 0.00 0.00
52 Week High 1.00
52 Week Low 0.36
CYTR Important Levels
Resistance 2 0.60
Resistance 1 0.59
Pivot 0.56
Support 1 0.55
Support 2 0.54
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.14 40.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
DCTH 0.14 40.00%
VRTA 4.50 38.46%
JRJC 2.11 28.66%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 2.25 25.00%
NEXS 0.10 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

CytRx Corporation (NASDAQ: CYTR)

CYTR Technical Analysis 2
As on 16th Aug 2017 CYTR Share Price closed @ 0.57 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.52 & Strong Sell for SHORT-TERM with Stoploss of 0.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
CYTR Target for August
1st Target up-side 1.24
2nd Target up-side 1.43
3rd Target up-side 1.62
1st Target down-side 0.7
2nd Target down-side 0.51
3rd Target down-side 0.32
CYTR Other Details
Segment EQ
Market Capital 47314736.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cytrx.com
CYTR Address
CYTR
11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
Phone: 310-826-5648
Fax: 310-826-6139
CYTR Latest News
Interactive Technical Analysis Chart CytRx Corporation ( CYTR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on CytRx Corporation
CYTR Business Profile
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.